Auriga Laboratories Obtains Rights To Market And Sell A New Product Indicated For The Treatment Of ADHD

Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company, announced today the signing of a license agreement with Outlook Pharmaceuticals, Inc., pursuant to which Auriga will have the exclusive rights to market and sell a new product indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the United States. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: